Immunotherapy and prostate cancer (Q35145709)

6 August 2017

1 reference

title

Immunotherapy and prostate cancer (English)

1 reference

6 August 2017

1 reference

1 reference

Joseph M Kaminski

1

1 reference

6 August 2017

James B Summers

2

1 reference

6 August 2017

Matthew B Ward

3

1 reference

6 August 2017

Mark R Huber

4

1 reference

6 August 2017

Boris Minev

5

1 reference

6 August 2017

publication date

1 June 2003

1 reference

6 August 2017

published in

Cancer Treatment Reviews

1 reference

6 August 2017

volume

29

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

199-209

1 reference

Teaching the immune system to fight cancer.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Dominance and crypticity of T cell antigenic determinants

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Induction of anti-self-immunity to cure cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Loss of HLA class I expression in prostate cancer: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

1 reference

7 January 2021

Identification of human cancers deficient in antigen processing

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Molecular characterization of defective antigen processing in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

A reassessment of the role of B7-1 expression in tumor rejection.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Fas ligand and immune evasion

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing fas-ligand: a mechanism of immune evasion

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

The basic science of gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Gene therapy for prostate cancer. New perspectives on an old problem

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Adenovirus and adeno-associated virus mediated gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Infection of the adrenal gland as a route to the central nervous system after viraemia with herpes simplex virus in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Herpes simplex virus hepatitis in macrophage-depleted mice: the role of massive, apoptotic cell death in pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Gene delivery and gene therapy with herpes simplex virus-based vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Vaccinia virus: a tool for research and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Cationic liposomes for direct gene transfer in therapy of cancer and other diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Increased expression of DNA cointroduced with nuclear protein in adult rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Design of a nonviral vector for site-selective, efficient integration into the human genome

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Stabilized plasmid-lipid particles: construction and characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Human prostate-specific antigen: structural and functional similarity with serine proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Molecular cloning of human prostate specific antigen cDNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Structure of peptides associated with class I and class II MHC molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Dendritic cell-based immunotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

A Phase II Study of [90Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Tumor therapy with targeted atomic nanogenerators

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Anti-tumor effects of toxins targeted to the prostate specific membrane antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Cellular mucins: targets for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Immune recognition of human colonic-tumour-associated MUC-2 mucins using an anti-peptide antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Augmenting the immunogenicity of carbohydrate tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Telomerase: a target for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Structure and function of telomeres

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Telomere length, aging, and somatic cell turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

A survey of telomerase activity in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Cytotoxic T cell immunity against telomerase reverse transcriptase in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Telomerase as a universal tumor-associated antigen for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Telomerase: the search for a universal cancer vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Dendritic cells: a link between innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Dendritic cell vaccines for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Interferon-beta treatment of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Cytokine therapeutics: lessons from interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Antiproliferative effect of interferons on human prostate carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Intratumoral depot interleukin-2 therapy inhibits tumor growth in Dunning adenocarcinoma of the prostate implanted subcutaneously in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

IL-12 regulates VEGF and MMPs in a murine breast cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Inhibition of cancer cell motility and invasion by interleukin-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

A potential role for interleukin-15 in the regulation of human natural killer cell survival

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900005-7

7 January 2021

10.1016/S0305-7372(03)00005-7

Identifiers

DOI

1 reference

6 August 2017

1 reference